During China’s October National Day, news of Merck’s investigational oral pill (Molnupiravir) for treating Covid-19 was received with great excitement and many questions: is a special drug finally born? Will the treatment of Covid-19 be similar to that for the common cold? Will the new drug become the panacea in ending the Covid-19 pandemic? However, shortly thereafter, reports from India indicated that the drug has “no significant efficacy” for patients with moderate Covid-19 symptoms, making it difficult at this time to determine the efficacy of Molnupiravir for treating Covid-19. We at Evergreen are not surprised; as we understand it, according to the 10 technical pathways of vaccine development and 10 EUA products approved by the FDA, every aspect of the fight against SARS-CoV-2 h

Dr.Charles Lee, CMO of EvergreenDr. Li Changqing, CMO of Evergreen Therapeutics (“Evergreen” or the “Company”) shared his excitement on the very intuitive demonstration of the efficacy of the EG-007 combination: “Simply comparing the size of tumor residual in the same animal trial, the average tumor weight after dual-drug treatment was approximately 730 mg, while after our three-drug regimen it was just over 300 mg.”EG-007 was the first drug candidate Dr. Li led after joining Evergreen. In mid-July this year, Dr. Li assumed position of Evergreen CMO. Subsequently in August, after two pre-IND meetings, the FDA approved the Phase III pivotal clinical trial protocol of EG-007 in combination with targeted drugs and anti-PD-1 antibody analogs for the treatment of advanced endometrial cancer. No